Montazeri Ali, Milroy Robert, Hole David, McEwen James, Gillis Charles R
Department of Public Health, University of Glasgow, UK.
Qual Life Res. 2003 Mar;12(2):157-66. doi: 10.1023/a:1022232624891.
A prospective study was conducted to measure quality of life in newly diagnosed lung cancer patients attending a chest clinic in a large teaching and district general hospital in a geographically defined area (northern sector of Glasgow, Scotland). Quality of life was assessed at two points in time, pre-diagnosis (baseline) and 3 months after diagnosis (follow-up) using three standard measures; the Nottingham Health Profile (NHP); the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and its lung cancer supplement (QLQ-LC13). Out of 133 lung cancer patients diagnosed during the study period, 129 patients (97%) were interviewed pre-diagnosis. Of these, only 63% of the patients had an active treatment. Ninety-six patients were alive at follow-up, of whom 82 patients were re-interviewed. Thus, only 82 patients who had complete data were used in the analysis. Comparing patients' pre-diagnosis and follow-up scores on the NHP, only sleep difficulties improved slightly. Patients reported increased perceived health problems of all other characteristics studied (energy, p = 0.0004; physical mobility, p = 0.0008). Similar results were observed on the EORTC questionnaires indicating that patients' functioning and global quality of life had decreased. The only significant improvement after 3 months was seen in patients' cough (p = 0.006). There were marked increases in hair loss (p < 0.0001), constipation (p = 0.007), and sore mouth (p = 0.0004). The findings suggest that patient-centred variables should receive sufficient consideration in the treatment of lung cancer. The study results clearly indicate that information on quality of life contributes to our understanding of patients' experiences of their cancer treatment.
在一个地理区域明确的地区(苏格兰格拉斯哥北部地区)的一家大型教学医院和地区综合医院的胸科诊所,对新诊断的肺癌患者进行了一项前瞻性研究,以测量其生活质量。在两个时间点对生活质量进行评估,即诊断前(基线)和诊断后3个月(随访),使用三种标准测量方法:诺丁汉健康量表(NHP);欧洲癌症研究与治疗组织生活质量问卷(EORTC QLQ-C30)及其肺癌补充问卷(QLQ-LC13)。在研究期间确诊的133例肺癌患者中,129例患者(97%)在诊断前接受了访谈。其中,只有63%的患者接受了积极治疗。96例患者在随访时存活,其中82例患者接受了再次访谈。因此,分析中仅使用了82例拥有完整数据的患者。比较患者在NHP上的诊断前和随访分数,只有睡眠困难略有改善。患者报告称,在研究的所有其他特征方面,感知到的健康问题有所增加(精力,p = 0.0004;身体活动能力,p = 0.0008)。在EORTC问卷上也观察到了类似结果,表明患者的功能和总体生活质量有所下降。3个月后唯一显著改善的是患者的咳嗽(p = 0.006)。脱发(p < 0.0001)、便秘(p = 0.007)和口腔疼痛(p = 0.0004)明显增加。研究结果表明,在肺癌治疗中应以患者为中心的变量应得到充分考虑。研究结果清楚地表明,生活质量信息有助于我们了解患者的癌症治疗体验。